ADYNOVATE

🇺🇸 United States

FDA Page

Effective Date: May 28, 2026
Approval ID: ef290433-997f-4e98-86d6-42f6a99d6d18
Products: 0 registered
Version: 24

Regulatory Information

Labeling Type

PLASMA DERIVATIVE

Status

Approved

Full Title

These highlights do not include all the information needed to use ADYNOVATE safely and effectively. See full prescribing information for ADYNOVATE. ADYNOVATE, (Antihemophilic Factor, Recombinant, PEGylated) Lyophilized Powder for Solution for Intravenous Injection Initial U.S. Approval: 2015

Quick Stats

Total Products0

Labelers0

Label Sections0

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.